Predict your next investment

DemeRx company logo
HEALTHCARE | Pharmaceuticals / Drugs
demerx.com

See what CB Insights has to offer

Founded Year

2010

Stage

Other Investors | Alive

About DemeRx

DemeRx is a clinical stage pharmaceutical development company. The company develops non-addictive treatments for drug addiction. It is based in Miami, Florida.

DemeRx Headquarter Location

1951 NW 7th Avenue Suite 600

Miami, Florida, 33136,

United States

Latest DemeRx News

DemeRx Inc. to Present at Wonderland Miami by Microdose

Nov 6, 2021

11/06/2021 | 03:55pm EDT Message : *Required fields Florida--(Newsfile Corp. - November 6, 2021) - DemeRx IB, Inc. ("DemeRx"), a company focused on developing ibogaine for the treatment of opioid use disorder (OUD), will be presenting at Wonderland Miami Conference by Microdose on November 9th, 2021, The Evolution of Ibogaine Treatment. DemeRx in joint partnership with atai Life Sciences received MHRA approval for DMX-1002 (Ibogaine) to commence a Phase 1/2a study as the first clinical trial in Opioid Use Disorder. The trial has begun enrollment and dosing of volunteers in the Phase 1 arm of the study. DMX-1002 is an oral formulation of ibogaine, a naturally occurring psychedelic product isolated from a West African shrub. In previously published non-controlled studies, ibogaine has demonstrated rapid and sustained efficacy in treating opioid use disorder and shown potential to be a disease modifying treatment for this vulnerable patient population seeking to end their intractable cycle of drug dependence. The Phase 1/2a trial is designed to assess safety, tolerability, pharmacokinetics, and efficacy, and the results will inform future studies in patients with opioid use disorder. We expect to obtain safety data from the phase 1 arm of this trial in early 2022. "DemeRx looks forward to bringing important clinical data from carefully designed, controlled studies to the existing literature on ibogaine, a compound with substantial history," said Deborah Mash, CEO and President of DemeRx. "We are hopeful that this early trial can begin to establish a safe and efficacious profile for Ibogaine, so that we can potentially offer a new option for patients seeking to break free from opioids who have far too few options." NOTES TO EDITORS About DemeRx, Inc. & DMX-1002 DemeRx, Inc. is a Miami-based clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the treatment of opioid use disorder and other addictions. DemeRx's mission is to advance the development of potential addictions treatments to prevent patient suffering, provide better treatment retention, and decrease illegal drug use. DemeRx is developing DMX-1002 for the treatment of opioid use disorder. DMX-1002 is a GMP drug product manufactured for human use. Contact Information

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DemeRx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DemeRx is included in 2 Expert Collections, including Psychedelics.

P

Psychedelics

231 items

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

DemeRx Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DemeRx Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.